Beat-to-beat variability of repolarization differentiates the extent of torsadogenic potential of multi ion channel-blockers bepridil and amiodarone

European Journal of Pharmacology

Volumn 596, Issue 1-3, 2008, Pages 127-131

  Takahara, Akira ^a   Nakamura, Yuji ^a   Sugiyama, Atsushi ^a,b  

^a UNIVERSITY OF YAMANASHI   (Japan)

^b Yamanashi Research Center of Clinical Pharmacology   (Japan)

Author keywords

Beat to beat variability of repolarization; Bepridil; Chronic atrioventricular block dog; QT interval prolongation; Torsades de pointes

Indexed keywords

AMIODARONE; ANCARON; BEPRICOR; BEPRIDIL; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARRHYTHMOGENESIS; ARTICLE; ATRIOVENTRICULAR BLOCK; BEAT TO BEAT VARIABILITY OF REPOLARIZATION; CHANNEL GATING; CHRONIC DRUG ADMINISTRATION; CONTROLLED STUDY; DOG; DRUG EFFECT; DRUG MECHANISM; DRUG SCREENING; FEMALE; HEART RATE VARIABILITY; HEART REPOLARIZATION; HOLTER MONITORING; MALE; NONHUMAN; PARAMETER; PRIORITY JOURNAL; QT INTERVAL; QT PROLONGATION; SINGLE DRUG DOSE; TORSADE DES POINTES;

AMIODARONE; ANIMALS; ANTI-ARRHYTHMIA AGENTS; ATRIOVENTRICULAR BLOCK; BEPRIDIL; DOGS; ELECTROCARDIOGRAPHY; FEMALE; HEART; HEART RATE; ION CHANNELS; MALE; TORSADES DE POINTES;

EID: 53049086219     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejphar.2008.08.018     Document Type: Article

References (48)

1. Abildskov J.A., and Lux R.L. Simulated torsade de pointes - the role of conduction defects and mechanism of QRS rotation. J. Electrocardiol. 33 (2000) 55-64
2. Anno T., Furuta T., Itoh M., Kodama I., Toyama J., and Yamada K. Electromechanical effects of bepridil on rabbit isolated hearts. Br. J. Pharmacol. 81 (1984) 41-47
3. Antzelevitch C. Ionic, molecular, and cellular bases of QT-interval prolongation and torsade de pointes. Europace 9 Suppl 4 (2007) iv4-iv15
4. Berger F., Borchard U., and Hafner D. Effects of the calcium entry blocker bepridil on repolarizing and pacemaker currents in sheep cardiac Purkinje fibres. Naunyn-Schmiedebergs Arch. Pharmacol. 339 (1989) 638-646
5. Brennan M., Palaniswami M., and Kamen P. Do existing measures of Poincaré plot geometry reflect nonlinear features of heart rate variability?. IEEE Trans. Biomed. Eng. 48 (2001) 1342-1347
6. Chiba K., Sugiyama A., Hagiwara T., Takahashi S., Takasuna K., and Hashimoto K. In vivo experimental approach for the risk assessment of fluoroquinolone antibacterial agents-induced long QT syndrome. Eur. J. Pharmacol. 486 (2004) 189-200
7. Duchene-Marullaz P., Kantelip J.P., and Trolese J.F. Effects of bepridil, a new antianginal agent, on ambulatory electrocardiography in human volunteers. J. Cardiovasc. Pharmacol. 5 (1983) 506-510
8. Fujiki A., Sakamoto T., Iwamoto J., Nishida K., Nagasawa H., Mizumaki K., and Inoue H. Pharmacological cardioversion of persistent atrial fibrillation with and without a history of drug-resistant paroxysmal atrial fibrillation. Circ. J. 70 (2006) 1138-1141
9. Hara Y., and Nakaya H. SD-3212, a new class I and IV antiarrhythmic drug, a potent inhibitor of the muscarinic acetylcholine-receptor-operated potassium current in guinea-pig atrial cells. Br. J. Pharmacol. 116 (1995) 2750-2756
10. Hil J.A., O'Brien J.T., Scott E., Conti C.R., and Pepine C.J. Effects of bepridil on exercise tolerance in chronic stable angina, a double-blind, randomized, placebo-controlled, crossover trial. Am. J. Cardiol. 53 (1984) 679-683
11. Hondeghem L.M., Carlsson L., and Duker G. Instability and triangulation of the action potential predict serious proarrhythmia, but action potential duration prolongation is antiarrhythmic. Circulation 103 (2001) 2004-2013
12. Ishizaka Y., Takahara A., Iwasaki H., Mitsumori Y., Kise H., Nakamura Y., and Sugiyama A. Comparison of electropharmacological effects of sotalol and bepridil assessed in the halothane-anesthetized dogs. Circ. J. 72 (2008) 1003-1011
13. Izumi D., Chinushi M., Watanabe H., Washizuka T., Okamura K., Komura S., Tanabe Y., Furushima H., and Aizawa Y. Bepridil for drug-refractory ventricular tachyarrhythmias. Intern. Med. 46 (2007) 119-124
14. + current. Circulation 103 (2001) 1317-1324
15. Kobayashi S., Reien Y., Ogura T., Saito T., Masuda Y., and Nakaya H. Inhibitory effect of bepridil on hKv1.5 channel current, comparison with amiodarone and E-4031. Eur. J. Pharmacol. 430 (2001) 149-157
16. Kodama I., Kamiya K., and Toyama J. Amiodarone, ionic and cellular mechanisms of action of the most promising class III agent. Am. J. Cardiol. 84 (1999) 20R-28R
17. + channels. J. Pharmacol. Exp. Ther. 291 (1999) 562-568
18. Manouvrier J., Sagot M., Caron C., Vaskmann G., Leroy R., Reade R., and Ducloux G. Nine cases of torsade de pointes with bepridil administration. Am. Heart J. 111 (1986) 1005-1007
19. + channels in guinea pig ventricular myocytes. J. Cardiovasc. Pharmacol. 26 (1995) 761-769
20. + channel current in guinea pig ventricular cells. Naunyn-Schmiedebergs Arch. Pharmacol. 358 (1998) 641-648
21. Nakazato Y., Yasuda M., Sasaki A., Iida Y., Kawano Y., Nakazato K., Tokano T., Mineda Y., Sumiyoshi M., Nakata Y., and Daida H. Conversion and maintenance of sinus rhythm by bepridil in patients with persistent atrial fibrillation. Circ. J. 69 (2005) 44-48
22. Sassine A., Masse C., Fajuri A., Hirsch J.L., Labrid C., and Puech P. Electrophysiologic effects of bepridil in the anesthetized dog studied by endocardiac electrodes. Am. J. Cardiol. 53 (1984) 1707-1711
23. Satoh T., and Zipes D.P. Rapid rates during bradycardia prolong ventricular refractoriness and facilitate ventricular tachycardia induction with cesium in dogs. Circulation 94 (1996) 217-227
24. Satoh Y., Sugiyama A., Takahara A., Chiba K., and Hashimoto K. Electropharmacological and proarrhythmic effects of a class III antiarrhythmic drug nifekalant hydrochloride assessed using the in vivo canine models. J. Cardiovasc. Pharmacol. 43 (2004) 715-723
25. Sicouri S., Moro S., Litovsky S., Elizari M.V., and Antzelevitch C. Chronic amiodarone reduces transmural dispersion of repolarization in the canine heart. J. Cardiovasc. Electrophysiol. 8 (1997) 1269-1279
26. Siddoway L.A., McAllister C.B., Wilkinson G.R., Roden D.M., and Woosley R.L. Amiodarone dosing, a proposal based on its pharmacokinetics. Am. Heart J. 106 (1983) 951-956
27. Singh B.N. Bepridil therapy: guidelines for patient selection and monitoring of therapy. Am. J. Cardiol. 69 (1992) 79D-85D
28. Somberg J., Torres V., Flowers D., Miura D., Butler B., and Gottlieb S. Prolongation of QT interval and antiarrhythmic action of bepridil. Am. Heart J. 109 (1985) 19-27
29. Sugiyama A., Ishida Y., Satoh Y., Aoki S., Hori M., Akie Y., Kobayashi Y., and Hashimoto K. Electrophysiological, anatomical and histological remodeling of the heart to AV block enhances susceptibility to arrhythmogenic effects of QT-prolonging drugs. Jpn. J. Pharmacol. 88 (2002) 341-350
30. Sugiyama A., Satoh Y., Shiina H., Takeda S., and Hashimoto K. Torsadegenic action of the antipsychotic drug sulpiride assessed using in vivo canine models. J. Cardiovasc. Pharmacol. 40 (2002) 235-245
31. 1 blocker terfenadine-induced torsades de pointes arrhythmias. Br. J. Pharmacol. 147 (2006) 634-641
32. Kr blockers. J. Pharmacol. Sci. 102 (2006) 396-404
33. Thomsen M.B., Verduyn S.C., Stengl M., Beekman J.D., de Pater G., van Opstal J., Volders P.G., and Vos M.A. Increased short-term variability of repolarization predicts d-sotalol-induced torsades de pointes in dogs. Circulation 110 (2004) 2453-2459
34. Thomsen M.B., Volders P.G., Beekman J.D., Matz J., and Vos M.A. Beat-to-beat variability of repolarization determines proarrhythmic outcome in dogs susceptible to drug-induced torsades de pointes. J. Am. Coll. Cardiol. 48 (2006) 1268-1276
35. Thomsen M.B., Oros A., Schoenmakers M., van Opstal J.M., Maas J.N., Beekman J.D., and Vos M.A. Proarrhythmic electrical remodelling is associated with increased beat-to-beat variability of repolarisation. Cardiovasc. Res. 73 (2007) 521-530
36. Toyoshima S., Kanno A., Kitayama T., Sekiya K., Nakai K., Haruna M., Mino T., Miyazaki H., Yano K., and Yamamoto K. QT PRODACT, in vivo QT assay in the conscious dog for assessing the potential for QT interval prolongation by human pharmaceuticals. J. Pharmacol. Sci. 99 (2005) 459-471
37. Usui T., Sugiyama A., Ishida Y., Satoh Y., Sasaki Y., and Hashimoto K. Simultaneous assessment of the hemodynamic, cardiomechanical, and electrophysiological effects of terfenadine on the in vivo canine model. Heart Vessels 13 (1998) 49-57
38. Van de Water A., Verheyen J., Xhonneux R., and Reneman R.S. An improved method to correct the QT interval of the electrocardiogram for change in heart rate. J. Pharmacol. Methods 22 (1998) 207-217
39. van Opstal J.M., Schoenmakers M., Verduyn S.C., de Groot S.H., Leunissen J.D., van Der Hulst F.F., Molenschot M.M., Wellens H.J., and Vos M.A. Chronic amiodarone evokes no torsade de pointes arrhythmias despite QT lengthening in an animal model of acquired long-QT syndrome. Circulation 104 (2001) 2722-2727
40. Verdouw P.D., and Scheffer M. Cardiovascular actions after intravenous and intracoronary administration of the slow channel blocker bepridil. Arzneimittelforschung 34 (1984) 21-25
41. Vos M.A., de Groot S.H., Verduyn S.C., van der Zande J., Leunissen H.D., Cleutjens J.P., van Bilsen M., Daemen M.J., Schreuder J.J., Allessie M.A., and Wellens H.J. Enhanced susceptibility for acquired torsade de pointes arrhythmias in the dog with chronic, complete AV block is related to cardiac hypertrophy and electrical remodeling. Circulation 98 (1998) 1125-1135
42. Ks, in guinea-pig ventricular myocytes. Br. J. Pharmacol. 128 (1999) 1733-1738
43. Wang K., Takahara A., Nakamura Y., Aonuma K., Matsumoto M., and Sugiyama A. In vivo electropharmacological effects of amiodarone and candesartan on atria of the chronic atrioventricular block dogs. J. Pharmacol. Sci. 103 (2007) 207-213
44. 2+ exchanger inhibitors. J. Pharmacol. Sci. 102 (2006) 7-16
45. Yasuda M., Nakazato Y., Sasaki A., Kawano Y., Nakazato K., Tokano T., and Daida H. Clinical evaluation of adverse effects during bepridil administration for atrial fibrillation and flutter. Circ. J. 70 (2006) 662-666
46. Yatani A., Brown A.M., and Schwartz A. Bepridil block of cardiac calcium and sodium channels. J. Pharmacol. Exp. Ther. 237 (1986) 9-17
47. Yoshida H., Sugiyama A., Satoh Y., Ishida Y., Yoneyama M., Kugiyama K., and Hashimoto K. Comparison of the in vivo electrophysiological and proarrhythmic effects of amiodarone with those of a selective class III drug, sematilide, using a canine chronic atrioventricular block model. Circ. J. 66 (2002) 758-762
48. Yoshida T., Niwano S., Inuo K., Saito J., Kojima J., Ikeda-Murakami K., Hara H., and Izumi T. Bepridil prevents paroxysmal atrial fibrillation by a class III antiarrhythmic drug effect. Pacing Clin. Electrophysiol. 26 (2003) 314-317